Global Oral Solid Dosage Contract Manufacturing Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The Oral Solid Dosage Contract Manufacturing Market size is expected to reach USD 71.04 Billion in 2034 from USD 41.20 Billion (2025) growing at a CAGR of 6.24% during 2026-2034.

The oral solid dosage (OSD) contract manufacturing market has grown significantly as pharmaceutical companies outsource production to specialized contract development and manufacturing organizations (CDMOs). Tablets and capsules remain the most common drug delivery forms, driving sustained demand. Outsourcing enables cost optimization, scalability, and compliance with global regulatory standards.

Growth drivers include patent expirations leading to generic drug production, increasing small-molecule pipelines, and the need for flexible manufacturing capacity. Technological advancements in high-potency APIs, continuous manufacturing, and quality control systems enhance efficiency. Pharmaceutical firms increasingly rely on CDMOs for formulation development and commercial-scale production.

Future prospects are robust, supported by expanding generic and specialty drug markets. Emerging economies offer cost-competitive manufacturing hubs. Investment in automation, digital quality management, and regulatory compliance will strengthen competitiveness. However, supply chain disruptions and stringent regulatory scrutiny may impact operational dynamics.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

Tablets
Capsules
Powders
Granules
Others

By Mechanism

Immediate Release
Delayed Release
Controlled Release

By End Use

Large Size Companies
Medium & Small Size Companies
Others

COMPANIES PROFILED

Catalent Inc, Lonza, Aenova Group, Boehringer Ingelheim International GmbH, Jubilant Pharmova Limited, Patheon Pharma Services, Recipharm AB, Corden Pharma International, Siegfried Holding AG, Piramal Pharma Solutions, AbbVie Contract Manufacturing, Next Pharma AB
We can customise the report as per your requirements.

Product Code: VMR11218732

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY PRODUCT 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Product
4.2. Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Capsules Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Powders Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Granules Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY MECHANISM 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Mechanism
5.2. Immediate Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Delayed Release Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Controlled Release Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY END USE 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast End Use
6.2. Large Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Medium & Small Size Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Product
- 7.2.2 By Mechanism
- 7.2.3 By End Use
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Product
- 7.3.2 By Mechanism
- 7.3.3 By End Use
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Product
- 7.4.2 By Mechanism
- 7.4.3 By End Use
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Product
- 7.5.2 By Mechanism
- 7.5.3 By End Use
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Product
- 7.6.2 By Mechanism
- 7.6.3 By End Use
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Catalent Inc
- 9.2.2 Lonza
- 9.2.3 Aenova Group
- 9.2.4 Boehringer Ingelheim International GmbH
- 9.2.5 Jubilant Pharmova Limited
- 9.2.6 Patheon Pharma Services
- 9.2.7 Recipharm AB
- 9.2.8 Corden Pharma International
- 9.2.9 Siegfried Holding AG
- 9.2.10 Piramal Pharma Solutions
- 9.2.11 AbbVie Contract Manufacturing
- 9.2.12 Next Pharma AB